These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 33338869)
41. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738 [TBL] [Abstract][Full Text] [Related]
42. Effective degradation of EGFR Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286 [TBL] [Abstract][Full Text] [Related]
43. A patent review of selective CDK9 inhibitors in treating cancer. Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897 [TBL] [Abstract][Full Text] [Related]
47. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566 [TBL] [Abstract][Full Text] [Related]
48. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335 [TBL] [Abstract][Full Text] [Related]
49. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525 [TBL] [Abstract][Full Text] [Related]
50. Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex. Lin R; Yang J; Liu T; Wang M; Ke C; Luo C; Lin J; Li J; Lin H Chem Biodivers; 2023 Aug; 20(8):e202300769. PubMed ID: 37349855 [TBL] [Abstract][Full Text] [Related]
51. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Xiao L; Liu Y; Chen H; Shen L Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701 [TBL] [Abstract][Full Text] [Related]
52. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia. Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320 [TBL] [Abstract][Full Text] [Related]
54. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein. Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516 [TBL] [Abstract][Full Text] [Related]